FDA Accepts Revance Resubmission for Frown Line Treatment
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
Older women undergoing breast reconstruction after mastectomy face slightly higher risks of complications but report better psychological well-being despite lower satisfaction with breast appearance, highlighting the need to weigh age-related risks and benefits when considering surgery.